Personalis to Present at the 23rd Annual Needham Virtual Growth Conference

Rhea-AI Summary

Personalis, Inc. (Nasdaq: PSNL), a leader in cancer genomics, announced its participation in the 23rd Annual Needham Virtual Growth Conference on January 13, 2021, at 2:45 p.m. Eastern Time. The company specializes in population sequencing and oncology, offering advanced molecular data to improve cancer treatment. Its ImmunoID NeXT Platform analyzes approximately 20,000 human genes and immune responses from a single tissue sample, supporting biopharmaceutical development. Personalis is recognized for its extensive sequencing operations and is the exclusive sequencing provider for the VA MVP.

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that management will present at the 23rd Annual Needham Virtual Growth Conference on Wednesday, January 13, 2021 at 2:45 p.m. Eastern Time.

About Personalis, Inc.

Personalis, Inc. is a leader in population sequencing and cancer genomics, with a focus on data, scale, efficiency and quality. Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to the VA MVP. In oncology, Personalis is transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The Personalis^® ImmunoID NeXT Platform^® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. The Personalis Clinical Laboratory is GxP-aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit www.personalis.com and follow Personalis on Twitter (@PersonalisInc).

View source version on businesswire.com: https://www.businesswire.com/news/home/20201228005002/en/

FAQ

What is Personalis, Inc. known for in the stock market?

Personalis, Inc. (PSNL) is recognized for its advancements in cancer genomics and population sequencing.

When is Personalis presenting at the Needham Virtual Growth Conference?

Personalis will present at the Needham Virtual Growth Conference on January 13, 2021, at 2:45 p.m. Eastern Time.

What is the ImmunoID NeXT Platform of Personalis?

The ImmunoID NeXT Platform is designed to provide comprehensive molecular data from a single tissue sample, analyzing around 20,000 human genes and immune responses.

Who is the exclusive sequencing provider for the VA MVP?

Personalis, Inc. is the sole sequencing provider for the VA MVP.

What certifications does the Clinical Laboratory of Personalis hold?

The Clinical Laboratory of Personalis is GxP-aligned, CLIA’88-certified, and CAP-accredited.